Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Sleep Apnea is characterized by several key symptoms that can significantly impact on your quality of life. The most ...

Background: The pathogenesis of daytime hypercapnia (PaCO 2 ≥ 45 mm Hg) may be directly linked to the existence of obstructive sleep apnea syndrome (OSAS) per se, although only some patients ...

With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency ...

Diagnostic overnight polysomnography was performed in the sleep center ... GP indicates general practitioner; OSA, obstructive sleep apnea; and PA, primary aldosteronism. Blood pressure (measured ...

Sleep apnea may lead to weight gain by disrupting sleep, affecting hunger hormones, slowing metabolism, and more. Lifestyle ...

People who have obstructive sleep apnea may have an increased risk of dementia if left untreated, according to a new study of ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Global warming is// expected to double the health burden of obstructive sleep apnea by the year 2100 * High number of ...

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, w | Drug Discovery And Development ...

Sleep also enables the body to repair and replenish cellular material that is damaged or depleted. Important bodily functions ...

People diagnosed with obstructive sleep apnea may face more than just poor sleep and tired mornings. A new study finds they ...